XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 7 Months Ended 9 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Jul. 31, 2022
Sep. 30, 2021
Dec. 31, 2022
Collaboration And Other Agreements [Line Items]              
Revenues $ 13,136 $ 26,007 $ 37,632 $ 37,108      
Deferred revenue, current 9,671   9,671       $ 9,988
Deferred revenue, net of current portion 58,538   58,538       59,480
I-Mab | I-Mab Biopharma Collaboration and License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment           $ 15,000  
Development and regulatory milestones recognized     $ 5,000        
Estimated variable consideration           $ 1,000  
One-time credit paid, percent     80.00%        
Revenues 0 600 $ 0 700      
One Time Millstone Credit             $ 4,500
I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply              
Collaboration And Other Agreements [Line Items]              
Revenues 0 300 0 1,100      
Incyte Corporation | RevenuesFromCMOAgreementsMember              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment         $ 10,000    
Revenues 1,600 $ 4,000 5,200 $ 4,000      
Deferred revenue 9,000   9,000        
Deferred revenue, current 7,500   7,500        
Deferred revenue, net of current portion $ 1,500   $ 1,500